Bioequivalence testing
Executive Summary
Strategy for bioequivalence testing of highly variable drug products will be discussed by FDA's Pharmaceutical Science Advisory Committee on April 14. On April 13, the committee will discuss a proposal for resolving issues related to the parametric tolerance interval test for dose content uniformity for inhalation products. The committee will also receive updates from the Clinical Pharmacology Subcommittee and on the progress of FDA's process analytical technologies effort. [To 1watch a webcast of this meeting, go to FDAAdvisoryCommittee.com]....
You may also be interested in...
Topical bioequivalence advisory committee
FDA's Office of Generic Drugs will present an update on its research into topical bioequivalence to the Pharmaceutical Science Advisory Committee at April 14 meeting. Discussion will focus on developing a decision tree that would classify topical products based on their site of action and the degree of formulation similarity. [Editor's Note: To 1watch a webcast of this meeting, go to 2www.FDAAdvisoryCommittee.com]. During the April 13-14, meeting, the committee will also discuss highly variable drugs, inhalation products and process analytical technologies (3"The Pink Sheet" March 22, 2004, In Brief)...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.